This inventor holds 2 USPTO granted patents and 5 published patent applications. Top assignees: Excision Biotherapeutics, Inc., Temple University. Active years: 2019-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Bedminster, NJ (US) (2019)
- Andover, NJ (US) (2022)
Company Filing History:
2 out of 2 
2 out of 423 
Years Active: 2019-2022
Title: Innovations by Thomas Malcolm in Gene Editing
Introduction
Thomas Malcolm is a notable inventor based in Bedminster, NJ (US), recognized for his contributions to the field of gene editing. He holds two patents that focus on innovative methods and compositions aimed at eliminating the risk of JC virus activation and progressive multifocal leukoencephalopathy (PML) during immunosuppressive therapy. His work is significant in advancing therapeutic strategies for patients undergoing such treatments.
Latest Patents
Malcolm's latest patents include groundbreaking methods for gene editing that target the JC virus genome. One of his patents describes a method of eliminating the risk of JC virus activation in subjects undergoing immunosuppressive therapy. This involves administering a gene editing composition that cleaves the target sequence in the JC virus genome, thereby disrupting the virus and eliminating the infection. Additionally, his pharmaceutical compositions include isolated nucleic acid sequences encoding CRISPR-associated endonucleases and various gene editing tools such as TALENs and ZFNs, which are designed to target specific nucleotide sequences in the JC virus genome.
Career Highlights
Throughout his career, Thomas Malcolm has worked with prominent organizations, including Excision Biotherapeutics, Inc. and Temple University. His experience in these institutions has allowed him to collaborate with leading experts in the field, further enhancing his research and innovation capabilities.
Collaborations
Malcolm has collaborated with notable colleagues such as Kamel Khalili and Kenneth I Kohn, contributing to the advancement of gene editing technologies and their applications in medical therapies.
Conclusion
Thomas Malcolm's innovative work in gene editing represents a significant advancement in the fight against viral infections during immunosuppressive therapy. His patents and collaborations highlight his commitment to improving patient outcomes through scientific innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile